An interventional study of Ambulate in Preterm Prelabor Rupture of Membranes (PPROM), sponsored by Cedars-Sinai Medical Center. Not yet recruiting at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Cedars-Sinai Medical Center · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Preterm Premature Rupture of the Membranes with a site in United States — 8 open to participants now, 10 under way, 1 of them phase 3. Preterm Premature Rupture of the Membranes · United States.
Among the 27 studies in Preterm Premature Rupture of the Membranes with a site in United States, this one is the 8th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2026, is one of 9 with no phase, and was the 27th registered.
76 studies on the registry are indexed under Preterm Premature Rupture of the Membranes; 18 are open to participants now.
Browse Preterm Premature Rupture of the Membranes studies →8 of the 27 studies in Preterm Premature Rupture of the Membranes with a site in United States are open now. Recruiting first, the newest first:
Alexa Henderson · Sites in United States
Women only
Eastern Virginia Medical School · Sites in United States
Ages 18–50 · Women only
Ohio State University · Sites in United States
Ages 18+ · Women only
Christina Chianis Reed · Sites in United States
Ages 18–64 · Women only
Washington University School of Medicine · Sites in United States
Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Preterm Premature Rupture of the Membranes studies recruiting now, 7 (64%) set no upper age limit and 4 (36%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 3 · Phase 4 7
First in 2004; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 91 across 50 interventional studies indexed under Preterm Premature Rupture of the Membranes.
Median enrollment 56 across the 21 interventional studies, 254 across the 6 observational. Of the 14 that completed or were terminated, 4 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 27 have an industry lead sponsor. The 10 most frequent:
Cedars-Sinai Medical Center is the lead sponsor of 457 studies on the registry; 108 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 49 (75%) have results posted.
Cedars-Sinai Medical Center has 1 study filed under Preterm Premature Rupture of the Membranes — fewer than ten, so there is no comparison to draw.
2 of the studies in Preterm Premature Rupture of the Membranes with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06396078Ohio State UniversityImprovement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) | 2026-12 |
| NCT05773014Washington University School of MedicineDigital vs. Speculum Exams for PPROM | 2027-03-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Preterm Premature Rupture of the Membranes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this quasi-experimental study is to determine if there are improved outcomes for patients with preterm prelabor rupture of membranes (PPROM) who walk daily. The main question it aims to answer is:
- Are patients with PPROM who walk at least 3500 steps per day more likely to stay pregnant longer than those who walk less?
Participants will be encouraged to walk ≥3500 steps per day from the time of diagnosis until delivery and their daily step counts will be recorded. Researchers will compare those who actually walk ≥3500 steps per day to those who walk less.
The primary objective of this study is to determine if there is increased latency to delivery for patients with PPROM who ambulate ≥3500 steps per day compared to those who ambulate less. The investigators have chosen a goal of 3500 steps as this equates to approximately 30 minutes of moderate-intensity walking, and ACOG endorses the US Department of Health and Human Services Physical Activity Guidelines which recommend at least 150 minutes of moderate intensity aerobic activity per week during pregnancy.
The secondary objective of this study is to determine whether there is a lower risk of adverse maternal and neonatal outcomes for patients with PPROM who ambulate ≥3500 steps per day compared to those who ambulate less. Maternal adverse outcomes that will be assessed include rate of intra-amniotic infection, placental abruption, umbilical cord prolapse, cesarean delivery for non-reassuring fetal heart tracing, and thromboembolic events. Neonatal adverse outcomes that will be assessed include gestational age at delivery, birth weight, APGAR score at 5 minutes, requirement for NICU admission, length of stay, and neonatal death. The investigators will also assess the average steps per day for each participant and type of smartphone (i.e. Android vs iPhone).
Inclusion criteria include patients admitted to Cedars-Sinai with PPROM between the gestational ages of 24w0d and 33w6d who have planned inpatient management of at least 7 days, a phone capable of monitoring and sharing step count, and a singleton or dichorionic twin gestation. Exclusion criteria include patients with malpresentation (specifically, transverse, footling breech, or funic presentation), active preterm labor, or active vaginal bleeding.
This is a quasi-experimental study. All patients will be encouraged to ambulate ≥3500 steps per day. Patients will then be categorized into two cohorts: those who ambulated ≥3500 steps per day and those who ambulated \<3500 steps per day. Outcomes will be compared between the two cohorts.
The duration of the study for each patient is the length of time from admission to delivery.
The study will be conducted at one site only, Cedars-Sinai.
At the time of study recruitment, patients will be given information about exercise in pregnancy and encouraged to ambulate at least 3500 steps per day. They will also be asked to share their daily step count via their smartphone health app with a member of the research team. All other antepartum, intrapartum, and postpartum care will be standard and/or per the primary obstetrician's discretion. After hospital discharge, a member of the research team will record the patient's daily step count and extract demographic information as well as obstetric and neonatal outcomes from the EMR.
Our primary outcome is the mean number of days of latency to delivery, and the investigators will use a Welch's t-test to assess the difference between our two study groups. The investigators will then use a multivariable linear regression analysis to account for potentially confounding variables.
For our secondary outcomes, the investigators will assess time from diagnosis to delivery using a log-rank test followed by a cox regression analysis. Additionally, maternal demographic and obstetric outcomes as well as neonatal outcomes will be compared using chi square and t-test for categorical and continuous variables, respectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All patients will be encouraged to ambulate ≥3500 steps per day
Behavioral: Ambulate
Ambulate ≥3500 steps per day
Days of latency until delivery
Time frame: From hospital admission to delivery
Number of participants who experience a thromboembolic event
Time frame: From admission until maternal hospital discharge, an average of 1-4 days after delivery
Number of participants who experience a postpartum hemorrhage
Postpartum hemorrhage is defined as EBL/QBL \>= 1000mL
Time frame: From admission until maternal hospital discharge, an average of 1-4 days after delivery
Number of participants who experience maternal sepsis
Time frame: From admission until maternal hospital discharge, an average of 1-4 days after delivery
Number of participants who are admitted to the Intensive Care Unit (ICU)
Time frame: From admission until maternal hospital discharge, an average of 1-4 days after delivery
Days of postpartum length of stay
Time frame: From admission until maternal hospital discharge, an average of 1-4 days after delivery
Mode of delivery
Vaginal delivery versus cesarean section
Time frame: Day of delivery
Estimated or quantitative delivery blood loss
Time frame: From admission until maternal hospital discharge, an average of 1-4 days after delivery
Number of participants who experience an intraamniotic infection
Time frame: From admission until maternal hospital discharge, an average of 1-4 days after delivery
Number of patients who experience a placental abruption
Time frame: From admission until delivery
Number of patients who experience an umbilical cord prolapse
Time frame: From admission until delivery
Spontaneous versus induced labor
Time frame: From admission until delivery
Indication for cesarean delivery
Only for patients who deliver via cesarean delivery
Time frame: Day of delivery
Gestational age at delivery
Time frame: Day of delivery
Neonatal birth weight
Time frame: Day of delivery
APGAR score at 5 minutes of life
APGAR score (Appearance, Pulse, Grimace, Activity, and Respiration) is on a scale from 0-10. Lower scores indicate that infants are more likely to require resuscitation.
Time frame: 5 minutes of life on day of delivery
Umbilical cord blood gas values
Arterial pH, CO2, and base excess
Time frame: Day of delivery
Number of neonates who require Neonatal Intensive Care Unit (NICU) admission
Time frame: From delivery until day of neonatal hospital discharge, varies based on gestational age at delivery
Neonatal length of hospital stay
Time frame: From delivery until day of neonatal hospital discharge, varies based on gestational age at delivery
Number of participants who receive at least one course of antenatal corticosteroids
Time frame: From admission until delivery
Number of participants who receive antenatal magnesium sulfate
Time frame: From admission until delivery
Number of neonatal deaths
Time frame: From admission until day of neonatal hospital discharge (or death when applicable), varies based on gestational age at delivery
Plan to share: No — To protect patient confidentiality
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Preterm Premature Rupture of the Membranes →